barbara
04-26-2009, 12:27 AM
I knew the ducks would finally have their day. This article is true. You will never find it on Quack Watch.
Article Date: 24 Apr 2009
SAFC Biosciences(R), a business segment within SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL), announced the introduction of EX-CELL(TM) EBx(R) cell growth and viral production media designed exclusively to support Vivalis' (NYSE Euronext: VLS) EB66(R) duck cells used in the commercial production of prophylactic and therapeutic vaccines. The new EX-CELL EBx media is expected to further enable EB66 licensees in the development of viral vaccine therapeutics. In addition, Vivalis plans to use the media in the cGMP manufacture of vaccine lots to support phase I/II clinical trials.
Vivalis, a leader in embryonic stem cell technology, has developed its fully-documented EB66 cell line from duck embryonic stem cells. The cell line fulfills all current industrial specifications for biologics manufacturing while retaining most of the desirable features of embryonic stem cells, such as genetic stability and indefinite cell proliferation. The EB66 cell line also provides key qualities for industrial applications, including growth in serum-free medium, proliferation in bioreactors at high cell densities such as suspension cells, and demonstrates high susceptibility to a broad range of genetically engineered and wild type animal and human viruses.
Commenting on the introduction of EX-CELL(TM) EBx(R), Bruce Lehr, SAFC Bioscience's Marketing Director, said: "Following our strategy of providing customer-centric solutions, we have worked closely with Vivalis to develop these new media to cGMP standards. Looking ahead, we expect to continue expanding our serum-free virus/vaccine media offer to keep pace with the market's burgeoning demand for safer, faster, more economical production processes."
Pierre Miniou, Vivalis Director, Business Development, added: "The EB66(R) cell line has created an immediate impact in the market as it circumvents the quality and quantity control issues associated with traditional chicken egg and primary chicken embryo fibroblasts, while eliminating the risk of contamination and the costs associated with serum for growing the fibroblasts. EB66 cells are fast becoming the recommended industry alternative for the safe, cost effective manufacturing of viral vaccines and recombinant proteins for human and veterinary use. This cell line has already been very well received by industry and has been licensed by pharmaceutical and biotechnology companies worldwide."
Article Date: 24 Apr 2009
SAFC Biosciences(R), a business segment within SAFC(R), a member of the Sigma-Aldrich Group (Nasdaq: SIAL), announced the introduction of EX-CELL(TM) EBx(R) cell growth and viral production media designed exclusively to support Vivalis' (NYSE Euronext: VLS) EB66(R) duck cells used in the commercial production of prophylactic and therapeutic vaccines. The new EX-CELL EBx media is expected to further enable EB66 licensees in the development of viral vaccine therapeutics. In addition, Vivalis plans to use the media in the cGMP manufacture of vaccine lots to support phase I/II clinical trials.
Vivalis, a leader in embryonic stem cell technology, has developed its fully-documented EB66 cell line from duck embryonic stem cells. The cell line fulfills all current industrial specifications for biologics manufacturing while retaining most of the desirable features of embryonic stem cells, such as genetic stability and indefinite cell proliferation. The EB66 cell line also provides key qualities for industrial applications, including growth in serum-free medium, proliferation in bioreactors at high cell densities such as suspension cells, and demonstrates high susceptibility to a broad range of genetically engineered and wild type animal and human viruses.
Commenting on the introduction of EX-CELL(TM) EBx(R), Bruce Lehr, SAFC Bioscience's Marketing Director, said: "Following our strategy of providing customer-centric solutions, we have worked closely with Vivalis to develop these new media to cGMP standards. Looking ahead, we expect to continue expanding our serum-free virus/vaccine media offer to keep pace with the market's burgeoning demand for safer, faster, more economical production processes."
Pierre Miniou, Vivalis Director, Business Development, added: "The EB66(R) cell line has created an immediate impact in the market as it circumvents the quality and quantity control issues associated with traditional chicken egg and primary chicken embryo fibroblasts, while eliminating the risk of contamination and the costs associated with serum for growing the fibroblasts. EB66 cells are fast becoming the recommended industry alternative for the safe, cost effective manufacturing of viral vaccines and recombinant proteins for human and veterinary use. This cell line has already been very well received by industry and has been licensed by pharmaceutical and biotechnology companies worldwide."